You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Claims for Patent: 11,590,128

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,590,128

Title:	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Abstract:	The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Inventor(s):	Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Assignee:	Genentech Inc , Hoffmann La Roche Inc , AbbVie Inc
Application Number:	US17/834,709
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,590,128
Patent Claims:	1. A method for treating acute myeloid leukemia (AML) in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in escalating doses, wherein the escalating doses comprise an initial dose of 100 mg of GDC-0199 per day. 2. The method of claim 1, wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab. 3. The method of claim 2, wherein the effective amount of the obinutuzumab is 1000 mg. 4. The method of claim 1, wherein the escalating doses further comprise a final dose of 400 mg of GDC-0199 per day. 5. A method for treating acute myeloid leukemia (AML) in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in escalating doses, wherein the escalating doses comprise a final dose of 400 mg of GDC-0199 per day. 6. The method of claim 5, wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab. 7. The method of claim 6, wherein the effective amount of the obinutuzumab is 1000 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.